News
Zacks Investment Research on MSN3d
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...
The FDA's approval of Biogen's Aduhelm for Alzheimer's disease has emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, although it acknowledges it ...
The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...
Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and Company’s donanemab be granted marketing ...
Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla (donanemab) also got a rejection from EU regulators.
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), on Friday declined to endorse Kisunla (donanemab), Eli Lilly’s (NYSE:LLY) candidate for early Alzheimer’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback